A 59-year-old man with a 4-year history of light chain myeloma relapsing after two preceding autografts and salvage therapy with thalidomide underwent a peripheral blood stem cell (PBSC) transplant from his HLAidentical sister after conditioning with 100 mg/m 2 melphalan. Graft-versus-host disease (GVHD) prophylaxis comprised cyclosporine. Despite pulmonary infiltrates and sinusitis at the time of the allograft, it was decided to proceed with the transplant because the myeloma was refractory and rapidly progressive. 
1
relapse is virtually universal in multiple myeloma. Allogeneic transplantation is the only potentially curative therapeutic option because of immunologically mediated graftversus-myeloma effects. 2 Allograft-related morbidity and mortality are substantial in myeloma patients, 2, 3 and a preceding autograft has been found to be a significant risk factor for poorer outcome. 4 The use of peripheral blood stem cells (PBSC) for allogeneic transplantation as a substitute for marrow makes the procedure potentially safer by allowing a higher CD34
+ cell dose to be administered, 5 and, in preliminary studies, is associated with lower relapse rates due to stronger graftversus-tumor effects. 6 Melphalan has not been conventionally thought to possess immunosuppressive properties although it has been used at the dose of 240 mg/m 2 as a single agent prior to marrow transplants from HLA-identical siblings. 7 Allogeneic transplantation after reduced-intensity (nonmyeloablative) conditioning has recently gained in popularity because of reduced morbidity and mortality. 8 We employ 100 mg/m 2 melphalan as a single agent with repeated infusions of donor-derived G-CSF-mobilized PBSC ('microallograft') to achieve alloengraftment and exploit graft-versus-tumor effects in patients who would otherwise not be considered for an allograft at all. 
Case report
A 59-year-old patient with a 4-year history of light chain myeloma underwent an allograft from his HLA-identical sister in January 2000. Prior therapy included multiple courses of chemotherapy, tandem autotransplantation with 200 mg/m 2 melphalan in August 1996 and January 1997, and maintenance therapy with interferon-␣2b and dexamethasone. Progression in January 1999 was treated initially with dexamethasone, then with thalidomide, 9 and eventually with a combination of the two; with responses lasting a few weeks to months each time.
At the time of the allograft, the disease was progressive on a combination of thalidomide and dexamethasone with 90% plasmacytosis in the marrow and over 7 g protein in the 24-h urine collection (95% monoclonal light chain). He had severe symptoms of sinusitis and a cough. The Karnofsky performance score (KPS) was 40%. Sinus CT scan showed extensive inflammatory changes in all paranasal sinuses but no periosteal or bony destruction. Chest CT scan showed bilateral pleural-based lower lobe infiltrates.
The infection improved slightly with antibacterial therapy but then improved no further. Due to the progressive nature of the disease, it was felt that proceeding with the transplant was urgent despite an active infection. The transplant plan was as follows: 100 mg/m 2 melphalan on day −2, infusion of G-CSF-mobilized donor PBSC on days 0, 21, 42 and 112 in the absence of active GVHD or infection, and GVHD prophylaxis with cyclosporine alone (target level of 350-400 ng/ml in the first 50 days). Cyclosporine was to be tapered once a week from day 50 and was to be discontinued by day 100. No growth factors were administered following the transplant. The transplant took place as planned. /l on day +12 and platelets recovered to 100 × 10 9 /l on day +20. Despite some aggravation of the symptoms of sinusitis as well as initial worsening on CT scanning, a conservative approach was chosen, especially since bilateral sinus endoscopy showed normal mucosa with no evidence of necrosis. The endoscopies helped drain the sinuses.
The day 21 PBSC infusion was omitted on account of active aspergillosis -it was felt that the potential risk of the development of GVHD requiring steroid therapy outweighed the benefit of PBSC infusion. The chest CT scan cleared completely and the sinuses almost completely by day +42, when he received the next infusion of PBSC as planned. The marrow examination on day 42 showed no plasmacytosis, and full donor-type chimerism on FISH. ABLC was decreased to three times weekly after 6 weeks of daily therapy and discontinued after 4 more weeks. Itraconazole was continued as maintenance therapy.
No acute GVHD was seen. The urine protein declined rapidly and on formal evaluation 75 days post transplant, the patient was in complete remission with no detectable marrow plasmacytosis or light chain excretion in the urine, full donor-type chimerism in the marrow on FISH, normal chest and sinus CT scans, and a KPS of 90%.
There was no chronic GVHD at 16 weeks, and a third aliquot of PBSC was infused in accordance with the treatment plan. At the last follow-up 9 months post transplant, the patient had no GVHD or detectable myeloma, with a normal chest CT scan and a KPS of 100%.
Discussion
This anecdotal case illustrates the feasibility of performing an allograft under extenuating clinical circumstances -progressive, refractory malignancy, extensive prior therapy, and active aspergillosis.
Most non-myeloablative allograft regimens are based on agents such as busulfan and cyclophosphamide. 11 Melphalan was chosen by us because it is clearly superior to other agents in myeloma. 12 The idea of repeated infusions of donor PBSC was to convert partial donor-type chimerism, if any, to full donor-type chimerism as well as to exploit graft-verus-tumor effects. 2, 13 Clearly, more data are needed to assess the usefulness of the repeated infusion of cells. PBSC were chosen rather than marrow to achieve more rapid immune reconstitution, and as a result, a beneficial impact on relapse rates. 6, 14 Preceding high-dose therapy has been found to be an important factor associated with higher treatment-related mortality and poorer survival after conventional allogeneic transplantation in myeloma. 4 A reduced-intensity conditioning regimen may overcome this obstacle in patients autografted previously as in this case.
It is possible that we may not have proceeded with the allograft if we had known the nature of the infection beforehand because aspergillosis is associated with a poor outcome in immunocompromised patients. In addition to effective anti-fungal therapy, a combination of ABLC and itraconazole in this case, 15 host defense mechanisms are important in treating this infection. This patient's immune system was compromised because of dexamethasone therapy, as well as progressive myeloma. Whether the patient's compromised immune system would have been capable of eradicating the fungus in the setting of progressive myeloma is questionable. The allogeneic cells controlled the myeloma in addition to providing a normal immune system, which, presumably, contributed to the control of the fungal infection.
Encouraged by the outcome of this patient, we have subsequently used the same allograft regimen in a patient with refractory, relapsed acute myeloid leukemia in the setting of active herpes infection. The patient had generalized varicella zoster, and herpesvirus type I ulcerative esophagitis and gastritis which were not responding to high-dose intravenous acyclovir as well as foscarnet; presumably due to the refractory malignancy. These infections resolved in the early post-transplant stage too.
We conclude that 100 mg/m 2 melphalan is a well-tolerated reduced-intensity regimen for allogeneic transplantation. Such strategies appear to allow allogeneic transplantation in patients who would never be considered eligible for conventional allografts. Long-term outcome data, including the possible development of significant chronic GVHD, must be assessed to see if non-myeloablative transplants can replace conventional allografts.
